N/A
N=22
Endothelial Function and Cardiac Output in RV Pacing
Bradycardia
Bottom Line
View on ClinicalTrials.gov: NCT00508196 ↗Enrolled (actual)
22
Serious AEs
0.0%
Results posted
Mar 2019
Primary outcome: Primary: Endothelial Function Assessed by Flow Mediated Vasodilatation — 1.96; 1.73 EndoPAT index (EnFI)
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- RVP-min (Other); RVP-max (Other)
- Age
- Adult, Older Adult · 21+ yrs
- Sex
- All
- Sponsor
- University of Dundee
- Primary completion
- Jul 2007
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Endothelial Function Assessed by Flow Mediated Vasodilatation |
1.96; 1.73 | — |
| SECONDARY B-type Natriuretic Pepetide |
104.3; 112.8 | — |
| SECONDARY Cardiac Output |
7.65; 7.05 | — |
Summary
Pacing from the right ventricle (as is current practice in patients implanted with permanent pacemakers for bradycardia), has been associated with worse outcomes particularly in heart failure patients. Recent clinical trials suggest that chronic right ventricular pacing (VP) is associated with worsening heart failure, increased strokes and atrial fibrillation. Hemodynamically, right VP results in delayed activation and contraction of the LV which can give rise to functional mitral regurgitation, shortened diastolic filling time and thus reduced coronary filling, as well as abnormal arterial pulsatile flow. The mechanisms for the deleterious effects of right VP in heart failure patients have not been previously investigated. Our aim of this study is therefore to investigate the hemodynamic effects of right VP in stable heart failure patients in terms of exercise cardiac output (CO, an important measure of myocardial function and prognosis), as well as endothelial function which may be deranged as a result of abnormal arterial pulsatile flow.
Eligibility Criteria
Inclusion Criteria
- Dual chamber pacemaker
- Intact AV node function
Exclusion Criteria
- Unstable angina, heart failure
- Inability to exercise
Data sourced from ClinicalTrials.gov (NCT00508196). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.